Endothelial Glycocalyx in Patients With Chronic Kidney Disease

Completed

• Conditions: Healthy; Chronic Kidney Diseases

• Registration Number: NCT04363567
• Lead Sponsor: Regional Hospital Holstebro

Brief Summary

The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease.

A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins.

Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

Detailed Description

The purpose of this study is to gain knowledge about how pronounced the EG are affected in varying degrees of chronic kidney disease compared with healthy controls assessed by

1. salt-blood test

2. release of endothelial glycocalyx proteins.

and to see how this correlates to

1. blood pressure (peripheral and central)

2. pulse wave velocity

3. albuminuria

4. coagulation system

5. vasoactive hormones (PRC, p-Ang-II, p-Aldo, p-ANP, p-BNP, p-AVP)

Study Timeline

• Study Start: 2016-11-07
• Primary Completion: 2019-06-25
• Study Completion: 2019-12
• Status Verified: 2020-04
• Study First Submitted: 2020-04-23
• Study First Submitted QC: 2020-04-23
• Last Update Submitted: 2020-04-23
• Study First Posted: 2020-04-27
• Last Update Posted: 2020-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 137

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Erythrocyte Salt Sensitivity	1 minute	Blood sample

Secondary Outcome Measures

Name	Time	Method
Syndecan-1	1 minute	blood sample
Heparan Sulfate	1 minute	blood sample
coagulation	1 minute	blood samples
blood pressure central and peripheral	1 minute	Mobil-O-Graph
Vasoactive hormones (PRC, Ang-II, Aldo, ANP, BNP, AVP)	1 minute	blood samples
pulse wave velocity	1 minute	Mobil-O-Graph
Albuminuria	1 minute	urine sample